DEVELOPING NOVEL IMMUNOTHERAPIES FOR CANCER WITH A FOCUS ON CD47 BLOCKADE

Trillium is developing biologics to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Our lead programs, TTI-621 and TTI-622, are directed against CD47, an innate immune checkpoint that functions as a “don’t eat me” signal to the immune system.